Yunfei Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunfei Pan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Feimin Zhao
Huzhou Univ, Huzhou Cent Hosp, Affiliated Cent Hosp, Dept Geriatr Med, Huzhou 313000, Zhejing, Peoples R China
1 shared publication Haihong Liao
Department of Internal Medicine-Oncology, Huzhou Central Hospital,Affiliated Central Hospital of Huzhou University, Huzhou, 313000, China
1 shared publication- Haihong Liao
Department of Medical Oncology, Huzhou Central Hospital, Huzhou, Zhejiang, China
1 shared publication - Jingjing Ren
Zhejiang University School of Medicine
1 shared publication Jiyuan Ying
Department of Gastroenterology, Research Center of Clinical Medicine,Affiliated Hospital of Nantong University, Nantong, 313000, China
1 shared publication- Junjun Shen
College of Horticulture, Northwest A&F University , Yangling 712100, Shaanxi , China
1 shared publication
Latest Publications
- Open Access
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 35-39
Associations between low muscle mass and clinical characteristics of health population in China
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 35-39
Open AccessAssociations between low muscle mass and clinical characteristics of health population in China
- RetractionOpen Access
- 25 July 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (3) , 1
[Retracted] MicroRNA‑874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the Transwell migration assay data shown in Fig. 3A were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 40: 2389‑2398, 2018; DOI: 10.3892/or.2018.6624]
- 25 July 2022
- Published by Spandidos Publications in Oncology Reports
- Vol. 48 (3) , 1
RetractionOpen Access[Retracted] MicroRNA‑874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the Transwell migration assay data shown in Fig. 3A were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 40: 2389‑2398, 2018; DOI: 10.3892/or.2018.6624]
- 20 April 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (18) , 2289-2300
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors
Background: Thyroid function abnormality (TFA) is one of the most common toxicities in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors. However, the risk factors ... Plain language summary Many patients with non-small-cell lung cancer are treated with immunotherapy, a type of treatment that uses the body’s natural immune system to fight diseases. We conducted a...
- 20 April 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (18) , 2289-2300
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors
Background: Thyroid function abnormality (TFA) is one of the most common toxicities in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors. However, the risk factors ... Plain language summary Many patients with non-small-cell lung cancer are treated with immunotherapy, a type of treatment that uses the body’s natural immune system to fight diseases. We conducted a...